Literature DB >> 15174915

Long-term outcome of infrainguinal percutaneous transluminal angioplasty.

Carl-Magnus Wahlgren1, Bo Kalin, Kent Lund, Jesper Swedenborg, Rabbe Takolander.   

Abstract

PURPOSE: To evaluate the long-term outcome of infrainguinal percutaneous transluminal angioplasty (PTA).
METHODS: Between 1991 and 1994, 77 patients (45 men; mean age 70 years, range 41-85) underwent infrainguinal PTA for occlusive disease. Patient records and angiographic examinations were reviewed to extract data to a patient register. A long-term (mean 9.3 years) follow-up examination of survivors was performed, including physical evaluation, walking impairment questionnaire (WIQ), and duplex ultrasound.
RESULTS: Cumulative primary and secondary patency rates, respectively, were 81% and 86% at 1 year, 65% and 73% at 5 years, and 12% and 17% at 10 years. Patency rates were better for patients with claudication than critical ischemia (p=0.02). Stenoses had better primary patency than occlusions (p=0.001), but there was no difference between stenoses <2 cm versus >/=2 cm. At long-term follow-up, patients with patent vessels (50%) had better ankle-brachial indices (p=0.01) and less pain in their calves (p=0.04) compared to patients with non-patent vessels, but there was no difference in walking capacity or quality of life. Generalized femoral artery disease (p=0.03) and diabetes mellitus (p=0.03) predicted poor survival.
CONCLUSIONS: Although the overall long-term patency of infrainguinal PTA is poor, the technique has a low morbidity and can be performed in selected patients with a reasonable long-term result.

Entities:  

Mesh:

Year:  2004        PMID: 15174915     DOI: 10.1583/03-1165.1

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  1 in total

1.  Long-term outcomes of infrainguinal bypass surgery for patients with diabetes mellitus and tissue loss.

Authors:  Heekyung Jung; Jayun Cho; Hyung-Kee Kim; Jihye Kim; Seung Huh
Journal:  Ann Surg Treat Res       Date:  2014-12-26       Impact factor: 1.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.